問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Endocrinology

Division of Cardiovascular Diseases

Kaohsiung Municipal Ta-Tung Hospital

Division of Endocrinology

更新時間:2023-09-19

李美月Lee, Mei Yueh
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -4 個月

篩選

List

20Cases

2024-01-16 - 2026-06-30

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)
  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    錠劑 膜衣錠

Participate Sites
10Sites

Not yet recruiting1Sites

2026-08-01 - 2028-12-31

Phase III

Not yet recruiting
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
  • Condition/Disease

    Obesity or Overweight

  • Test Drug

    注射液

Participate Sites
11Sites

Not yet recruiting1Sites

2025-03-01 - 2030-06-30

Active
A phase III, randomized, double-blind, placebo-controlled, event-driven trial was conducted to evaluate the effect of Baxdrostat in combination with Dapagliflozin compared to Dapagliflozin alone on the risk of first-time heart failure and cardiovascular death in participants at high risk of developing heart failure.
  • Condition/Disease

    The time elapsed before the first occurrence of any of the following events: • Hospitalization due to HF • Non-hospitalized HF • Death due to CV

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
18Sites

Recruiting18Sites

2024-02-01 - 2028-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2023-02-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2024-08-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2010-01-01 - 2013-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2024-02-26 - 2026-07-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

1 2